Randomized trial · people

Semaglutide: 14.9% weight loss at 68 weeks in STEP 1

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In this large trial, adults without diabetes on weekly semaglutide plus a lifestyle program lost much more weight than those on placebo, and more of them stopped treatment because of gut side effects.

Kind
Randomized trial
Studied in
People
Number studied
1961
Published
2021
Journal
N Engl J Med

What they tested

The team tested whether a once-weekly 2.4 mg semaglutide shot, added to a lifestyle program, helps adults with overweight or obesity lose weight.

How the study was done

A double-blind, randomized, placebo-controlled trial in 1961 adults without diabetes who had a BMI (body-mass index, weight relative to height) of 30 or more, or 27 or more with at least one weight-related health problem. People were assigned 2 to 1 to weekly semaglutide or placebo (a dummy shot) under the skin for 68 weeks, and both groups also got a lifestyle program.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

Model. Individual results vary.

PepVault for iPhone

Taking semaglutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

By week 68, body weight fell by 14.9% on average in the semaglutide group and by 2.4% in the placebo group, an estimated difference of 12.4 percentage points. In kg, the change was -15.3 kg with semaglutide and -2.6 kg with placebo. A loss of 5% or more was reached by 86.4% of the semaglutide group versus 31.5% on placebo, and a loss of 15% or more by 50.5% versus 4.9%. Nausea and diarrhea were the most common side effects, mostly mild to moderate and fading over time, and 4.5% on semaglutide stopped treatment due to gut side effects versus 0.8% on placebo.

What it doesn’t show

The trial ran 68 weeks and left out people with diabetes, so it does not show longer-term results or results in that group. It was funded by Novo Nordisk.

The paper

Wilding et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021.

The compound

More studies on Semaglutide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking semaglutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo